Delivery Device Patents on GLP-1 Receptor Agonists-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Delivery Device Patents on GLP-1 Receptor Agonists

Published:2024-02-05 Issue: Volume: Page:
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Alhiary Rasha¹,Gabriele Sarah¹,Kesselheim Aaron S.¹,Tu S. Sean²,Feldman William B.¹

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts

2. West Virginia University College of Law, Morgantown

Abstract

This study analyzed the US Food and Drug Administration–listed patents on glucagon-like peptide 1 (GLP-1) receptor agonists to determine their claim characteristics and the potential barriers they pose to generic entry.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2814942/jama_alhiary_2024_ld_240003_1706916565.81401.pdf

Reference6 articles.

1. Patents and regulatory exclusivities on GLP-1 receptor agonists.;Alhiary;JAMA,2023

2. Patenting strategies on inhaler delivery devices.;Demkowicz;Chest,2023

3. Patents and regulatory exclusivities on FDA-approved insulin products: a longitudinal database study, 1986-2019.;Olsen;PLoS Med,2023

4. Frequently asked questions on patents and exclusivity. US Food and Drug Administration (FDA). Accessed December 20, 2023. https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity

5. In re Lantus Direct Purchaser Antitrust Litig., 512 F. Supp. 3d 106 (D. Mass. 2020). Casetext. Accessed January 23, 2024. https://casetext.com/case/in-re-lantus-direct-purchaser-antitrust-litig-1

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP